To coincide with the International Day against Drug Abuse and Illicit Trafficking on 26 June 2012, the United Nations (UN) General Assembly (GA) held an ‘informal’ debate in New York on the issue of drugs and crime as a threat to development. 

 suggests the real threat, however, remains the same old tired and failed thinking that is entrenching, rather than reducing, harms from the international illegal drug trade.

The call for this debate reflects UN discussions about transnational organised crime and its link to the illicit drug trade. In September of last year, UN Secretary General Mr Ban Ki Moon set up a UN taskforce, to be led jointly by the UN Department for Political Affairs and the UN Office on Drugs and Crime (UNODC), to mobilise the UN in a co-ordinated and coherent response.

The challenge to the UN of developing a system-wide response on the issue of drugs and organised crime should not be taken lightly. For many years, civil society actors have been calling for UN agencies to ‘speak as one’ on an evidence and rights- based response to reducing drug-related harm among people who use drugs.

HIV prevention in particular has been at the top of this agenda. There has been some progress on this issue, with broad acceptance across UN bodies (after many years of sustained civil society advocacy) of life-saving harm reduction interventions such as needle and syringe programmes and opioid substitution therapy as key interventions for the HIV response.

However, in recent months, we have witnessed a concerning roll-back by the UNODC on harm reduction and a misrepresentation of the agreed best strategy for HIV prevention among people who use drugs. This was well illustrated by my colleagues from the International Network of People who Use Drugs and Harm Reduction International in their guest editorial in the May 2012 edition of this publication. There, they discussed the censorship of civil society voices at this year’s 55th Session of the Commission on Narcotic Drugs and moves by UNODC to reframe abstinence-based drug dependence treatment as effective HIV prevention.

The UNODC’s misguided leadership on this issue is particularly worrying given it is the lead UN agency for responding to HIV prevention among people who use drugs under its mandate as a co-sponsor of UNAIDS. These recent developments highlight the ever-pernicious tendency to promote zero-tolerance approaches to drug use in an unfortunate recycling of the powerful ‘drugs as a threat’ narrative, despite the overwhelming evidence for both the failure and negative consequences of this approach.

It is this ‘drugs as a threat’ narrative that was used to frame the GA debate on 26 June. While there is absolutely no doubt that the power and reach of transnational organised crime and the activities in which such groups are engaged seriously undermine global development objectives enshrined in the Millennium Development Goals, presenting the issue in these terms reinforces the idea that people who use drugs, farmers engaged in producing drug-linked crops and the ‘little fish’ in drug distribution networks are also the ‘threat’.

This conveniently ignores the fact these groups are often the most marginalised in society and their involvement in the drug trade is based on a complex combination of factors such as socio-economic status, marginalisation, vulnerability and geography. The ‘drugs as a threat’ discourse has justified punitive measures towards consumers of drugs, crop eradication schemes and resistance to pragmatic harm reduction measures on both the demand and supply sides of the drug market.

The actual GA debate was chaired by Mr Yuri Fedotov, the Executive Director of the UNODC. As predicted, it was fairly uninspiring, which is typical of these large diplomatic gatherings. There were the many routine and hollow statements from most member states echoing those we hear each year at the CND. There were, however, a few progressive interventions that reflect the recognition by an increasing number of governments that the drug control system is in need of modernisation and reform.

The US, for so long the main proponent for prohibition, reiterated its statement that we need to prioritise treatment over punishment. Guatemala robustly defended its call for a review of current drug policies and Luxembourg highlighted the need to take under serious consideration the recommendations of the Global Commission on Drug Policy.

These cracks in the consensus are heartening. Yet, to really shift the debate towards reform, there needs to be clear acceptance of a number of inconvenient truths – the greatest of which is that the huge political and financial commitments to eradicating the illicit drug market have failed. The global drug trade has not been contained and is estimated to be worth some US$300 billion, most of which is in the hands of organised crime.

The second inconvenient truth is that many of the security and law enforcement-focused strategies employed to this end have only served to exacerbate the problems: the illegality of the market fuels the profits of organised crime and drug market violence; the criminalisation of people who inject drugs drives the HIV epidemic and leads to the overburdening criminal justice and prison systems; and harsh supply reduction strategies lead to the destruction of the livelihoods of some of the most marginalised communities for whom the only existing viable economic option is the drug trade.

In understanding the multi-faceted nexus between drugs and development and how to respond effectively and appropriately, there must be a coherent strategy in which drug control objectives do not adversely affect the same communities that development policies are designed to support but that instead are integrated, sophisticated and pragmatic.

The real threat to development would be to complacently recycle wasteful, failed and counterproductive strategies.

This article was initially published in Matters of Substance, August 2012.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.

Drugs and development: The real threat

The success of the global HIV response depends on effective HIV prevention for the 16 million people who inject drugs worldwide. Needle and syringe programmes have repeatedly been proven to prevent HIV by reducing the need to re-use or share potentially contaminated injecting equipment. However, it has been estimated that just 8% of people who inject drugs have access to these programmes – with just two needles and syringes distributed per injector per month. As a result of poor coverage, inadequate resources and paraphernalia laws in some countries that prevent people from carrying syringes, many people who inject drugs continue to use unsterile needles and syringes.

An emerging body of evidence suggests that changing the types of needles and syringes that are used could massively reduce HIV transmission. The evidence is still limited to laboratory studies and mathematical models – but has shown enough promise to warrant inclusion in recent hepatitis guidance from the World Health Organization.

The basic premise is this: all needles and syringes retain some fluid (i.e. blood and/or drug solution) once the plunger is fully depressed – this is known as “dead-space”. In some “high dead-space” designs, fluid is retained in the tip of the syringe, the hub of the needle and the needle shaft itself. In other “low dead-space” designs, fluid is only retained in the needle itself (see image). The difference can be 40-times less fluid in the low dead-space syringes.

In laboratory experiments simulating common injection practices, low dead-space syringes retained up to 1,000 times less blood. Therefore, a person who shares a low dead-space syringe is less likely to be exposed to HIV. Modelling exercises suggest that switching people who inject drugs from high dead-space to low dead-space syringes could prevent or reverse injection-related HIV epidemics.

But this effect now needs to be proven in reality. Crucially, low dead-space needles and syringes tend to only be available in smaller sizes – which are no good if people need larger ones (due to the types of drugs, or where on the body they are injecting). Changing from one type of syringe to another must only be done in full consultation with people who inject drugs, and with alternative syringes still available for those who need them. At the same time, work is on-going to try and convince syringe manufacturers to make further low dead-space products and options available in the right sizes and at the right prices.

But this is one area of research to watch closely – a potential game changer for harm reduction efforts in many countries. The developments to date have been excellently summarised in a newly published article by Dr William Zule and colleagues – available here (subscriptions may be needed) – and further work is planned to determine exactly what impact this relatively simple intervention has on the ground.

Saving lives with dead-space?

Evolving out of the Global Drug Survey, drugs meter is a tool that allows people to get non-judgemental feedback on their drug use. Adam Winstock explains.

For the last decade or so, with the help of some great colleagues, I have managed to get lots of people to answer questions about their drug use by collaborating with media organisations like 

. However, while I got to write papers and participants got to read the results, I felt that the Global Drug Survey (GDS) could provide an even more beneficial service. This led me to develop the drugs meter, an anonymous way for anyone to gauge their drug use, which, I hope will encourage people to make positive health choices in a non-judgemental way.

For most people, for most of the time, use of substances is primarily a source of pleasure and does not incur serious harm to themselves or others. Many people are able to self-regulate their use – they dabble for a while and stop – and others who run into problems are able to change the way they use. But some people don't recognise when their drug use is causing themselves or others harm.

Some people who take lots of drugs look at their friends and think everyone does the same.

I spend my working day as a consultant addiction psychiatrist in London with people who use heroin and crack, alongside other drugs and alcohol. People who are dependent on drugs and/or are in treatment represent the minority of people who use, or have used, drugs or alcohol, and almost all started using drugs in a way that did not cause them serious harm. The journey to problematic drug use may have taken several years, but no one is interested in people who use drugs before they develop serious problems or are causing a nuisance to society. There is no guidance for people who use most drugs about what constitutes safer levels of drug use. This is because most governments take the stance that all drug use is bad and the only way to avoid drug-related harm is to not use drugs at all. Although many governments embrace the concept of harm reduction, most is aimed at the minority of people who use heroin or inject. The hidden masses of drug users, those 2-3 million people who wont ever see a drug service kind of get left behind.

Getting people to change their behaviours is hard. The last three decades have seen a growth in individual psychological approaches to encourage behaviour change, with motivational interviewing and brief interventions being the most widely evidenced. While these have been applied to the full range of unhealthy behaviours, they typically require face-to-face contact with health professionals and disclosure by the individual. More recently, the theories of behavioural economics and social normative feedback have been explored to help craft simple large-scale approaches to motivating behavioural change – such approaches aim to ‘nudge’ people’s behaviours towards healthier and happier choices. The principal is simple.

So are people interested in how their use of drugs and alcohol compare to others? As part of the 2011 Global Drug Survey (GDS), we asked participants if they were interested in knowing how their use of drugs or alcohol compared to other people. About 70 per cent said they were, while another 20 per cent said maybe.

We asked over 12,000 people how they thought their use of drugs and alcohol compared to other people who had used that drug recently, and the findings were amazing.

However, we need to explain that for comparison we used other people who had filled in the Global Drug Survey. That might not be a fair comparison group but, given it was people from across the world, mostly in their 20s or 30s and with enough of an interest to fill in a survey about drug use, we don’t think it’s a bad comparison group.

Here are some examples of what we found from the UK data. Just under 20 per cent of people who were judged as alcohol dependent using the AUDIT screening tool thought their drinking was average or less than average compared to other drinkers. Just over 15 per cent of people who were smoking cannabis 20 or more days per month thought their use was average or less than average compared to other cannabis smokers, when in fact they were in the top 30 per cent of all cannabis smokers in our sample. Over 50 per cent of people using 4g or more of cocaine per month thought they were average or below average users when in fact they were in the top 20 per cent of all cocaine users in the sample. This tells us something about how people want to see themselves, as well as those they choose to compare themselves with. Like most of us, our participants probably compared themselves with their mates. So if you do lots of drugs and all your mates do lots of drugs it probably seems like everyone is doing lots of drugs. If all your mates drink a lot, then heavy drinking might seem like average drinking.

Drugs meter is designed to allow people to compare themselves to others like them – well, at the moment it compares you to everyone else but once we hit 50,000 (we are at about 20,000 to date) people we’ll allow you to choose your peer groups based on gender, country, age, sexuality and musical taste. Drugs meter is different to general mass harm reduction approaches by making information personal. In order to make informed choices people need personally relevant, objective information about their use of drugs. Drugs meter allows people to get rapid and objective feedback on their drug use and to compare themselves to others, ‘nudging’ them to be safer. It also offers simple tools to reduce risks associated with drug use and intoxicated related sexual behaviour and flags up when use might be causing problems. Drugs meter does tell not people what to do. It simply provides an anonymous, safe place where people can think about their use and check out the risks they face – or help a friend they think may be in trouble.

Drugs meter is not funded by any government and does not tell a person that their use of drugs is safe. If they are in the bottom 10 per cent of cocaine users it reminds them that only a tiny percentage of their population has used cocaine in the last year.

So what’s the feedback so far? Since its online launch at the end of July, more than 5,000 people have completed the drugs meter, adding to the 15,000 people who contributed their baseline data through the GDS 2011/12 survey. Seventy-five per cent would recommend it to friends, 80 per cent said it got them to think them to think about their use of drugs and alcohol in a way that was helpful, 75 per cent said it was accurate or very accurate in the way it assessed their use and 25 per cent said they would use less, or use is an way that caused them less harm as a result.

All ten drugs meter apps are now available for your smart phone and we are developing overdose and high-risk sex and injecting meters at present. We are working with local DATs to promote drugs meter, gather good quality data on drug use trends and ensure that drugs meter gets used as widely as possible. It’s free!

Interested? Please feel free to share drugs meter with your friends and colleagues. You can find it at 

Drugs Meter: This time it’s personal

Rubem Cesar, executive director of Viva Rio

On Monday, July 9th, the Brazilian Commission on Drugs and Democracy (CBDD) and Viva Rio launched a national campaign to change the law on drugs in Brazil.

Public support for the campaign, Drug Law: It’s Time to Change, has exceeded expectations. While the organizers hoped to collect 50,000 signatures in the first 30 days of the campaign, that number was reached in just three days.

The campaign hopes to reform law 11.343/2006 by collecting one million signatures calling for Brazil’s National Congress to support more effective and equitable drug legislation in the country.

While the existing law technically allows for a partial decriminalization of possession for personal use, the law does not make a clear distinction between people who use drugs and people with intent to distribute. This gap is resulting in the arrest of thousands of drug users that are trialed as drug traffickers.

Since its implementation in 2006, the number of people imprisoned for carrying drugs has doubled, rising from around 60,000 to 120,000. Many of these prisoners have never committed any other major crimes, have no ties to organized crime and were only carrying small quantities of drugs when arrested.

With campaign signatures now skyrocketing with over 80,000 Brazilian and international supporters, CBDD and Viva Rio have decided to present the bill to the to the president of Brazil’s National Congress this August.

Simultaneous to its official presentation, the bill will also be uploaded on the online public debate forum, e-democracy. Through this mean, citizens around the country will be able to engage in the transparent process of discussing the proposed bill and sharing their suggestions for change.

Some of the proposals that will be presented in the new bill include moving the issue of drugs from the realm of public security to that of health and social assistance; decriminalizing drug use and establishing clear differences between people who use drugs and dealers. The bill should also ensure quality treatment for people who use drugs, as well as support for networks and families.

We believe that all of these measures will bring justice to the thousands of drug users who have been subject to draconian punishments and have been deprived of support systems in which they can find help without having to fear years behind bars.

To sign a petition today, go online at http://www.eprecisomudar.com.br/.

Make your voice heard! It’s time to change!

Brazil’s “Drug Law: It’s Time to Change” Campaign Turns Viral

As a participant at last week’s 19th International HIV/AIDS Conference, I was reminded of President Fernando Henrique Cardoso’s and UNDP Administrator Helen Clark’s call to armsearlier in July that there is a new prescription for the AIDS response: ‘courage is needed’.

The event was a pivotal moment – it was the first time that an international AIDS conference has been held on US soil, and this was made possible because President Obama overturned the travel ban for people living with HIV to enter the US. However, the conference also starkly highlighted one of the fundamental barriers to a scaled up, sustainable and rights-based response to the epidemic – many sex workers and people who use drugs were unable to enter the US and attend the conference because they are deemed as criminals under US law. In an attempt to remedy this great failure of this year's conference, two hubs, one focusing on drug use and the other on sex work, were organised prior to and during the conference to ensure that the voices of these vulnerable groups be heard.

The criminalisation of sex work and drug use fuels the HIV epidemic, undermining the many hugely positive and exciting scientific breakthroughs that the HIV response can take credit for. These include increased access to antiretroviral treatment and the critical importance of HIV treatment as prevention. Both HIV prevention and treatment are of equal importance in a rights-based approach. However, in a resource-constrained environment it is arguably more cost-effective to prevent HIV transmission in the first place. For people who inject drugs, this means primary HIV prevention measures such as the provision of sterile injecting equipment and opioid substitution treatment.

Our efforts to reach zero new infections will always be fighting the tide if policy and legislative barriers continue to inhibit an effective HIV response. This issue has been pertinently highlighted recently both by the Global Commission on Drug Policy and the Global Commission on HIV and the Law. Both Commissions call for the decriminalisation of drug use and the removal of legal impediments to harm reduction interventions for people who inject drugs as part of a comprehensive HIV response.

Although many people from the global drugs movement could not be in Washington (and the conference was all the poorer because of their absence) there were several impressive sessions at the conference on HIV and drug use. The Harm Reduction and Drug Policy networking zone in the Global Village, organised by Harm Reduction Coalition was definitely a highlight and enabled the holding of many important sessions that did not get into the main programme. These included the launch of the Global State of Harm Reduction report by Harm Reduction International and an overview of the Community Action on Harm Reduction project, among others.

Within the main programme, one of the most compelling speeches was made by Debbie McMillan in the Thursday plenary entitled ‘Making Waves: The Changing Tide of HIV and Drug Use’. Debbie highlighted the multi-faceted and complex relationship between criminalisation and vulnerability to HIV – sex work, drug use, and discrimination on the basis of race, sexual identity, gender, incarceration and ultimately HIV status. Her speech encapsulates the point by President Cardoso, Helen Clark and other leaders last week, such as Michel Kazatchkine and Michel Sidibe – we must put human rights front and centre of the HIV response.

We know what to do, we know how to do it – now we just need the political courage to turn the tide.

AIDS 2012 – Time for courage if we are going to turn the tide

The Tenth Biennial International conference on Alcohol, Drugs and Society in Africa organised by the Centre for Research and Information on Substance Abuse (CRISA) is one of the few events that provide opportunities to discuss issues related to drugs and substance use in Africa. The conference, focusing on ‘Social Determinant of Substance Abuse in Africa: From Knowledge to Action’, is timely and necessary since substance use is increasing across the continent, while adequate interventions are scarce in terms of policy reform and the provision of evidence-based services.

The scientific papers presented at the conference provided insights into many social factors that influence drug use among Nigerians and other African countries. This has contributed to reducing the wide gap in sparse data on drug use in Nigeria and Africa as a whole. However, much more research is still needed to get a clear picture of the drug consumption situation in the region and understand how best to tackle the phenomenon.

One major reoccurring theme at the conference was that of drug use among young people. As a member of Youth RISE, a youth-led international network established to reduce the risks and harms associated with substance use and drug policy amongst young people, this was of particular interest for me. Young people are often most affected by drug use, but also by badly designed drug policies and programmes. They are also particularly subject to stigma and discrimination, which tends to drive them away from life-saving harm reduction and evidence-based drug treatment services services, when those actually exist.

Another element which strikes me from the conference is the need for much more collaboration between academics/researchers, policy makers and civil society organisations from the region. This is crucial if we want to move from knowledge to action – while research in the region is necessary to learn more about the drug use situation and related harms, civil society organisations can engage with the government and provide services that will seek to reduce these harms. Unfortunately, such a dialogue space is currently absent in Nigeria. Although this conference was an interesting, and important, step in the good direction, much more is needed if we want drug policies to truly respond to drug use and its related harms among young people and the whole of society.

Drug policy in Africa: Perspectives from the CRISA Conference

Today, there is overwhelming evidence that harm reduction and evidence-based drug dependence treatment are highly effective interventions in reducing drug-related harms. Despite the evidence, certain governments continue to promote punishment as the main response to drug use. This is the case in many Asian countries where compulsory centres for drug users continue to be used as the primary response to drug use. These centres are often run by law enforcement officials instead of health and social workers, and “treatment” generally consists of beatings, humiliations, starvation and forced labour.

Many NGOs and UN officials from around the world advocate strongly for the closure of these centres. This is the case, for example, in a recent join statement from UN agencies on the issue.

Nepal is one of the countries where compulsory centres for drug users are common practice. In Kathmandu, the capital of the country, there are more than fifty such centres. Whereas some of these centres offer friendly treatment services for people who use drugs, most of them use ill treatment and torture practices in the name of drug treatment.

The first rehabilitation centre to have adopted such an arrest & punishment approach to drug dependence is called Narconon Nepal, and is run by former police officers. Other rehabilitation centres are run by “recovering dependent users”. It is common practice in Nepal for people who use drugs (including those going to harm reduction services) to be forcibly picked up by rehab outreach workers. Most of the time, these workers do so in collaboration with the local police. Once in the centres, the main rationale is that of “no pain, no gain” when users undergo “treatment” – this involves beatings and other ill treatment, while high fees are being charged to users and their family upon entry in the centres. These agencies work in close collaboration with the police and the Ministry of Home Affairs to make society “drug free”.

The reach that these centres have on the media is equally worrying, as their main message consists of demonising users and harm reduction interventions. This can have a very negative effect on the Nepalese population in terms of knowledge on drug use and reducing drug-related harms, and further stigmatises people who use drugs in the country.

It is high time that Nepal changes its policy on drug dependence treatment to ensure that services are based on global evidence and human rights.

Rehabilitation in Nepal: Stop using punishment as treatment for people who use drugs

On 26th June 2012, the United Nations (UN) General Assembly held an 'informal' debate on Drugs and Crime as a Threat to Development. The debate was moderated by Yuri Fedotov, and the UN Secretary General gave an (unfortunately very bland) opening speech.

As is to be expected with events dominated by diplomatic niceties, there was very little real debate and a lot of hollow prepared statements from member states, as we have become accustomed to at CND. That said, there were a few meaningful interventions, and we could observe a continuing trend of normalisation of references to decriminalisation, legalisation, and drug policy reform. The German delegation also called for a strong focus on long-term strategies of sustainable development.

Many delegations emphasised the importance of civil society, which of course didn't change the fact that NGO statements were relegated to the last few minutes of the day, which limited the number of such statements because of time constraints.

The Guatemalan Minister of Foreign Affairs gave a robust argument in favour of his country's call for fundamental review of drug strategies, the US repeated its CND call to focus more on treatment than punishment, and the Luxembourg Ambassador stated that the UN should be giving serious consideration to the recommendations of the Global Commission, and asked the panel for their views.

The Chairman of INCB, Raymond Yans, in response gave a garbled explanation of his reasons for opposing legal reform, in a few short minutes contradicting himself repeatedly ('this is a matter for member states, but here is the INCB's position'), and aiming a dig at Uruguay for weakening the international consensus, thereby breaking the convention of not criticising individual countries.

IDPC gave an NGO statement that called on the UN to lead the debate on reform, and to give a greater role to the health, development and human rights agencies. We also ran a side event on the previous day, organised in conjunction with the Guatemalan Mission, and with presentations from their foreign Minister Harold Caballeros, UNDP Latin America Director Heraldo Munoz, and Coletta Youngers of WOLA. We laid out the case for reform to an audience of 80 participants from New York missions and UN offices.

This debate will not have any direct result, but it is a good sign that the wider United Nations structures are discussing the drug policy issue beyond Vienna, and we took the opportunity to distribute our papers and key messages to a broad new audience.

UN debates on drug policy

The third the World Federation Against Drugs was held in May 2012 in Stockholm, Sweden, a country which has become the symbolic home of those 'restrictive' drug policies the Forum celebrates. An IDPC representative joined the curious mix of people who gravitated to the event: a sprinkling of those making a career out of fortifying the drug prohibition industry; a selection of familiar drug war zealots; and some individuals, probably very well-intentioned, there to support treatment and prevention.

The prevailing mood was one of bewilderment, anger and resentment, summed up by Victor Ivanov as he railed against the 'locomotive of the global drug legalisation movement’ whose objective is to 'legalise transnational organised crime' (sic). Russia’s treatment system is notoriously harsh and patently ineffective, but Ivanov was, philosophically speaking, on home territory here, and nobody was going to interfere, even in the name of basic conceptual coherence. The attendees were characterised by a kind of bunker mentality, being quite convinced that they face a shadowy network of well-armed billionaires determined to distort the evidence and lead the public pied-piper style into a maelstrom of addiction and misery.

Nonetheless, the organisation’s own attitude toward evidence is ambivalent at best. ‘Drug policies are too important to be left to drug experts,’ opined WFAD president Sven Olov Carlsson, who also announced that the Russian representation was ‘especially welcome’.

Maria Larsson, Sweden’s Minister of Health, rose to confirm that every time she goes to the Commission on Narcotic Drugs in Vienna, she encounters ‘a co-ordinated campaign to liberalise drug laws’. The bloated coffers and highly organised cadres of a ruthless and conspiratorial opposition was a theme repeatedly invoked throughout the event. Robert Dupont, a former Whitehouse drug tsar, then attempted to underpin the proceedings with a platform of pseudo-science, describing drug addiction as a ‘chemical slavery’ grounded in the hijacking of the ‘mammalian brain’ (this part of the brain, he expounded helpfully, ‘is not the human brain’). Dupont crowned his intervention by proudly characterising the assembled crusaders as ‘modern Vikings’. There was a press conference given by representatives of the US, UK, Russia, Italy and Sweden, at which the press was prohibited from asking questions. The tone of the proceedings was eccentric, and at times frankly bizarre. It was deeply disturbing to witness Gus Jaspert, the Home Office representative, aligning the UK with this movement.

Four overall themes emerged as the weapons with which the WFAD plans to counter the machinations of George Soros and his fellow super villains.

Use the language of human rights, which has up to now been commandeered by the harm reduction lobby.

Talk to the public about children, especially the Convention on the Rights of the Child.

There was no new research, no examples, other than the Swedish, in which repressive prohibition has succeeded; the sole argument made was that 'drug legalisation' would make things even worse. The IDPC representative left with the impression that these people were obsessed with harm reductionists and legalisers, whom they believe are actively seeking to increase drug use. It was difficult to credit, listening in to the discussions of this angry and confused subculture, that almost all the world's governments agree with them.

Tales from the World Forum Against Drugs 2012

In recent months we have seen several Latin American initiatives to promote alternatives to drug control based in prohibition, while Europe has remained fairly silent on the issue. This may be because of difficulties posed by the diversity of views among European Union (EU) member states or perhaps it is because the EU has become a little complacent about public health and harm reduction. Either way, Europe is failing to lead the global debate on drug policy reform and in several EU member states pragmatic approaches towards the issue of drugs are under threat from political, ideological and financial pressures.

The Global Commission on Drug Policy and the International Drug Policy Consortium took this discussion to Brussels last month. On May 29, we co-organised a seminar “Modernising the global drug control system – Can Europe lead?” at the European Parliament. During the event, co-hosted by the Member of Parliament (MEP) Nikos Chrysogelos, we called on the EU to break the taboo on drug policy reform, and for EU institutions to show true leadership in global drug policy debates.

Michel Kazatchkine and Pavel Bem, the two Commissioners who participated in the panel discussion, highlighted the fact that a drug policy rationale that is based on zero-tolerance and the harsh punishment of people who use drugs has failed to curb the global drug market. Instead, we have seen a raft of serious negative consequences as a result of the over-reliance on policies that prioritise supply reduction, incarceration and tough law enforcement, these include an increase in the reach and power of organised crime, deepening the marginalisation of vulnerable communities and an HIV epidemic among people who inject drugs.

It was a positive experience to be facing a room full of MEPs who did not shy away from discussing the difficult issues during our joint meeting with the Global Commission. MEP Sir Graham Watson (UK), for example, declared, “I would like to plead for moving away from prohibition”. Mr Chrysogelos (Greece) added, “Since prohibitive policies have failed in their primary objectives and they have proven ineffective, with a clear overweight of cost over benefits, there is an urgent need to reform them towards better regulation that would reduce the harms to users, society and the economy”. The remarks of Pierre Vimont, the Secretary General of the European External Action Service (EEAS), were also positive. While acknowledging the difficulties faced by the EU in holding a unified view on drug policy, he did make it clear that it was necessary for EU representatives and EU focal point diplomats from around the world to achieve a coherent and agreed discourse on drug policy.

On the afternoon of May 29, IDPC and the Global Commission held a civil society seminar on similar issues. Participants at the seminar shared a belief that it is important for the new EU Drugs Strategy to be based on evidence, and that regional leadership is important for many member states. At the same time, the role of civil society and grassroots activism at country level should not be neglected, as it is to a large extent the member states that are shaping the future European strategy. Balanced and well-functioning national drug policies, which respect human rights and public health principles, backed by civil society and general public support form a strong argument for policymakers who represent their societies at international forums. The discussions also touched upon issues related to the willingness of the EU to engage in meaningful debate around drug policy reform and harm reduction, and strategies that could be implemented to encourage more leadership among EU institutions.

These two seminars clearly reflect the fact that a number of MEPs and the EEAS are interested in engaging in meaningful drug policy reform debates, whereas the European Commission and the DG-Justice seem to be more reluctant to show leadership on the drugs issue, at a time when the EU is reviewing its Drugs Strategy. Nevertheless, we were encouraged by the European Council’s conclusions on the EU Drugs Strategy released last week, which explicitly call for a balanced drug policy based on public health and human rights. We hope that the new EU Drug Strategy will follow this direction and that better leadership will be shown by all EU institutions to engage in a much needed debate on drug policy reform.

Can Europe lead the way to global drug policy reform?

Today in Australia, politicians hailing from different parties called on the government to task the Productivity Commission to investigate the adequacy of the country’s drug laws, including the economic and social costs of law enforcement measures on illicit drugs. They reason that the entry of the Productivity Commission will help to depoliticise and inject evidence into the debate on drug law reform—a debate that is timely given the widespread (though sometimes merely private) acknowledgement amongst policymakers, experts and the public that current approaches are not working.

The call for an official review of Australia’s drug laws rides on a wave of national debate on the need for drug law reform stimulated by the media, and the Australia 21 report The prohibition of illicit drugs is killing and criminalising our children and we are all letting it happen released in April this year. The Australia 21 report was based on a roundtable discussion involving former high level politicians and policymakers, and community representatives. It considers the costs and benefits of Australia’s existing policies, and concludes that they have failed in their fundamental objective of protecting Australians from the harms of drug use and markets. It points out the alternative options to prohibition that other parts of the globe are starting to consider—including de-penalisation, decriminalisation, legalisation, regulation and taxation—and declares that “[i]t is time to reopen the national debate about drug use, its regulation and control.”

It appears that a national debate on the need for drug policy reform has indeed opened in Australia. However it is sobering to note that the prospect for reform remains a serious political challenge, given Prime Minister Julia Gillard shut down any discussion of a change in drug policy upon the release of the Australia 21 report, and public debate on the topic appears to remain deeply divided. Nevertheless the initiative taken by parliamentarians today to ensure a rational evaluation of Australia’s existing policies is an exciting development. There is hope yet that Australia may become a regional, even global, leader on the reform of drug policies to confront the damaging impacts caused by existing prohibition-based measures.

Growing support for rational evaluation of drug policies in Australia

Along with several colleagues from IDPC and Release, I attended the conference of the ISSDP last month. Set in the rather beautiful, historic city of Canterbury (it was in fact right next to the cathedral), the theme for this year’s event was the exploration of the ways that empirical research studies influence drug policies. There were numerous interesting presentations, and it would be impossible to mention more than a fraction of them here.

Of most significance to IDPC, however, was the plenary session featuring critical discussion of the Report of the Global Commission on Drug Policy. Mike Trace, IDPC Chair, opened the session with a defence of the Report. He reminded the audience, that this publication was always intended as a political intervention, yet despite that, he stood by the general thrust of the data on which the report was based.

Eminent US academic Professor Peter Reuter then spoke critically of the Global Commission Report, outlining briefly the shortcomings of some of the data it contained. ‘Nonetheless,’ he went on, ‘I come to praise Caesar, not to bury him.’ He listed the high calibre public figures who made up the Commission, and suggested that the real importance of the Report was that such well-respected individuals had very publically aligned themselves with the failure of the present drug control system and the need for open discussion of reform. The Report had done its job, he said, by drawing the attention of mainstream media and politics to the drug policy question, and the Commission should now quietly retire. He added that the Commission might have been more radical in its recommendations, a point echoed by (the equally eminent) Robin Room.

As an observer with, as it were, one foot in each camp of the academic research/policy activist divide, I found many of the discussions stimulating, one or two soporific, and some positively useful.

However, my impression is that the conference was not entirely successful in fulfilling its brief. On the ISSDP’s web site, the organisation’s stated objectives include ‘to improve the interface between researchers and policy makers’. If we broaden this a little to include not just policy-makers but the policy community (NGOs, civil servants, etc), there were times when academic researchers and the wider policy community appeared to exist in parallel universes. To a large extent, this is due to the differing institutional frameworks and cultures involved, which do not always share the same languages or possess equivalent types of formal social status. It is to be hoped that the conference will continue as an interface, and attempt to more effectively bridge this divide, with both sides viewing the conference as a learning process.

The attempt made by the ISSDP to be more geographically inclusive and broaden out the discussion to include a few presentations from Latin America and South East Asia should be noted. There is still further work to be done to stimulate academic discussion and research on drug policy in countries other than those in Western Europe, North America and Australasia. The next conference will take place in Bogota, Colombia and will be the first time the conference has been held outside Europe or the US.

Blog